BACKGROUND AND AIM: Partially hydrolyzed guar gum (PHGG) is a water-soluble, non-gelling dietary fiber with a wide range of uses in clinical nutrition. The aim of this prospective study was to investigate the effect of guar gum on colonic transit time (CTT) and symptoms of chronic constipation. METHODS: We enrolled patients fulfilling Rome III criteria for chronic constipation. CTT was measured before and at the end of treatment. After a 2-week run-in period, patients received 5 mg PHGG daily for 4 weeks. During study period, patients kept daily symptoms, stool and laxative usage diaries. They also recorded their symptom-related satisfaction weekly and treatment adverse events. RESULTS: Forty-nine patients received treatment; 39 (80 %) completed the study. Treatment significantly reduced colon transit time, from 57.28 ± 39.25 to 45.63 ± 37.27 h (p = 0.026), a reduction more prominent in slow transit patients (from 85.50 ± 27.75 to 63.65 ± 38.11 h, p = 0.016). Overall, the weekly number of complete spontaneous and spontaneous bowel movements increased significantly (p < 0.001); the latter correlated significantly with the acceleration of CTT in the overall population and in slow transit patients (B = 0.382; p = 0.016 and B = 0.483; p = 0.023, respectively). In addition, the number of bowel movements with straining decreased (p < 0.001) and stool form improved (p < 0.001), while days with laxative intake and days with abdominal pain decreased (p = 0.001 and p = 0.027, respectively). CONCLUSION: Four-week PHGG use accelerates colon transit time in patients with chronic constipation, especially in those with slow transit, and improves many of their symptoms including frequency of bowel movements.
BACKGROUND AND AIM: Partially hydrolyzed guar gum (PHGG) is a water-soluble, non-gelling dietary fiber with a wide range of uses in clinical nutrition. The aim of this prospective study was to investigate the effect of guar gum on colonic transit time (CTT) and symptoms of chronic constipation. METHODS: We enrolled patients fulfilling Rome III criteria for chronic constipation. CTT was measured before and at the end of treatment. After a 2-week run-in period, patients received 5 mg PHGG daily for 4 weeks. During study period, patients kept daily symptoms, stool and laxative usage diaries. They also recorded their symptom-related satisfaction weekly and treatment adverse events. RESULTS: Forty-nine patients received treatment; 39 (80 %) completed the study. Treatment significantly reduced colon transit time, from 57.28 ± 39.25 to 45.63 ± 37.27 h (p = 0.026), a reduction more prominent in slow transit patients (from 85.50 ± 27.75 to 63.65 ± 38.11 h, p = 0.016). Overall, the weekly number of complete spontaneous and spontaneous bowel movements increased significantly (p < 0.001); the latter correlated significantly with the acceleration of CTT in the overall population and in slow transit patients (B = 0.382; p = 0.016 and B = 0.483; p = 0.023, respectively). In addition, the number of bowel movements with straining decreased (p < 0.001) and stool form improved (p < 0.001), while days with laxative intake and days with abdominal pain decreased (p = 0.001 and p = 0.027, respectively). CONCLUSION: Four-week PHGG use accelerates colon transit time in patients with chronic constipation, especially in those with slow transit, and improves many of their symptoms including frequency of bowel movements.
Authors: N H Alam; R Meier; T Rausch; B Meyer-Wyss; P Hildebrand; H Schneider; C Bachmann; E Minder; B Fowler; K Gyr Journal: Clin Nutr Date: 1998-06 Impact factor: 7.324
Authors: G C Parisi; M Zilli; M P Miani; M Carrara; E Bottona; G Verdianelli; G Battaglia; S Desideri; A Faedo; C Marzolino; A Tonon; M Ermani; G Leandro Journal: Dig Dis Sci Date: 2002-08 Impact factor: 3.199
Authors: Luigi Russo; Paolo Andreozzi; Francesco P Zito; Letizia Vozzella; Ivana G Savino; Giovanni Sarnelli; Rosario Cuomo Journal: Saudi J Gastroenterol Date: 2015 Mar-Apr Impact factor: 2.485
Authors: Peter I Duncan; Catherine F Enters-Weijnen; Nashmil Emami; Peter McLean; Tiago Nunes; Maurice Beaumont; Rafael Crabbe; Kevin Whelan; S Mark Scott; Niek J deWit; Teunis Weits; Gabriela Bergonzelli; Diederick E Grobbee Journal: Nutrients Date: 2018-07-19 Impact factor: 5.717
Authors: Simon J Reider; Simon Moosmang; Judith Tragust; Lovro Trgovec-Greif; Simon Tragust; Lorenz Perschy; Nicole Przysiecki; Sonja Sturm; Herbert Tilg; Hermann Stuppner; Thomas Rattei; Alexander R Moschen Journal: Nutrients Date: 2020-04-28 Impact factor: 5.717
Authors: Stella C M Heemskerk; Adriënne H Rotteveel; Jarno Melenhorst; Stéphanie O Breukink; Merel L Kimman; Carmen D Dirksen Journal: J Gastroenterol Hepatol Date: 2019-08-22 Impact factor: 4.029